Department of Forensic Sciences, Oslo University Hospital, P.O. Box 4950 Nydalen, Oslo 0424, Norway.
Center for Psychopharmacology, Diakonhjemmet Hospital, Forskningsveien 13, Oslo 0373, Norway.
J Anal Toxicol. 2024 Jun 11;48(5):380-387. doi: 10.1093/jat/bkae024.
The general use of cocaine is increasing in recent years, while the trend for 3,4-methylenedioxymethamphetamine (MDMA) is less clear. The relationship between blood concentrations and impairment is poorly understood, which complicates interpretation. The aims of this study were to report prevalence and blood concentrations of cocaine and MDMA in drugged drivers, and to investigate the relationship between blood concentrations and impairment. Samples of whole blood were collected from apprehended drivers in the period 2000-2022, and a clinical test of impairment (CTI) was simultaneously performed. The samples were initially analyzed for cocaine and MDMA using gas chromatography-mass spectrometry (until 2009 and 2012, respectively), and later using ultra-high-performance liquid chromatography-tandem mass spectrometry. Overall, cocaine was detected in 2,331 cases and MDMA in 2,569 cases. There were 377 and 85 mono cases of cocaine and MDMA, respectively. In the mono cases, the median cocaine concentration was 0.09 mg/L (range: 0.02-1.15 mg/L), and 54% of the drivers were clinically impaired. The median MDMA concentration was 0.19 mg/L (range: 0.04-1.36 mg/L), and 38% were clinically impaired. There was a statistically significant difference in the median cocaine concentration between drivers assessed as not impaired (0.07 mg/L) and drivers assessed as impaired (0.10 mg/L) (P = 0.009). There was also a significant effect of the blood concentration of cocaine (adjusted odds ratio [aOR] = 6.42, 95% confidence interval [CI] = 1.13-36.53, P = 0.036) and driving during the evening/night-time (aOR = 2.17, 95% CI = 1.34-3.51, P = 0.002) on the probability of being assessed as impaired on the CTI. No significant differences were found for MDMA. Many drivers are not assessed as impaired on a CTI following cocaine or especially MDMA use. For cocaine, a relationship between blood concentrations and impairment was demonstrated, but this could not be shown for MDMA.
近年来,可卡因的普遍使用呈上升趋势,而 3,4-亚甲二氧基甲基苯丙胺(MDMA)的趋势则不太明显。血药浓度与损伤之间的关系尚未得到充分了解,这使得解释变得复杂。本研究的目的是报告吸毒驾驶员中可卡因和 MDMA 的流行率和血药浓度,并探讨血药浓度与损伤之间的关系。在 2000 年至 2022 年期间,从被捕驾驶员处采集全血样本,并同时进行临床损伤测试(CTI)。最初使用气相色谱-质谱法(分别用于 2009 年和 2012 年之前)和后来的超高效液相色谱-串联质谱法分析样本中的可卡因和 MDMA。总体而言,在 2,331 例中检测到可卡因,在 2,569 例中检测到 MDMA。可卡因和 MDMA 的单一组别有 377 例和 85 例。在单一组别中,可卡因的中位浓度为 0.09mg/L(范围:0.02-1.15mg/L),54%的驾驶员存在临床损伤。MDMA 的中位浓度为 0.19mg/L(范围:0.04-1.36mg/L),38%的驾驶员存在临床损伤。在未受损(0.07mg/L)和受损(0.10mg/L)驾驶员中,可卡因的中位浓度存在统计学显著差异(P=0.009)。可卡因血药浓度(调整比值比[aOR]6.42,95%置信区间[CI]1.13-36.53,P=0.036)和夜间/夜间驾驶(aOR 2.17,95%CI 1.34-3.51,P=0.002)对 CTI 评估受损的概率有显著影响。MDMA 则没有发现显著差异。许多驾驶员在使用可卡因或特别是 MDMA 后,并未在 CTI 上被评估为受损。对于可卡因,已经证明了血药浓度与损伤之间存在关系,但 MDMA 则无法证明。